Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Get Free Report) was the target of a significant drop in short interest during the month of October. As of October 15th, there was short interest totalling 130,500 shares, a drop of 21.9% from the September 30th total of 167,200 shares. Approximately 0.8% of the company’s shares are short sold. Based on an average daily volume of 73,300 shares, the days-to-cover ratio is presently 1.8 days.
Cyclo Therapeutics Price Performance
CYTH stock opened at $0.75 on Monday. The business has a 50-day moving average price of $0.76 and a 200 day moving average price of $1.09. The company has a market capitalization of $21.32 million, a P/E ratio of -0.75 and a beta of -0.38. Cyclo Therapeutics has a 1-year low of $0.59 and a 1-year high of $2.12.
Cyclo Therapeutics (NASDAQ:CYTH – Get Free Report) last released its quarterly earnings data on Thursday, August 15th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.07). The firm had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.40 million. Cyclo Therapeutics had a negative net margin of 1,830.27% and a negative return on equity of 2,741.89%. On average, analysts anticipate that Cyclo Therapeutics will post -0.72 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Read Our Latest Report on CYTH
About Cyclo Therapeutics
Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.
Read More
- Five stocks we like better than Cyclo Therapeutics
- 3 Monster Growth Stocks to Buy Now
- ASML Stock Slides – A Buying Opportunity in Semiconductors?
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- 3 Stocks to Score from 40% YoY Data Center Capex Spending in 2025
- 3 Best Fintech Stocks for a Portfolio Boost
- IBM Stock Has Never Looked So Exciting
Receive News & Ratings for Cyclo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.